Explore 3 Stock Ideas & Industry Insights Download Free Report

18889881171
Shopping Cart 0
countryflagUS
Login

Nuvalent Inc

Healthcare US NUVL

94.02USD
3.84(4.26%)

Last update at 2026-06-04T20:00:00Z

Day Range

90.4995.07
LowHigh

52 Week Range

38.7889.39
LowHigh

Fundamentals

  • Previous Close 90.18
  • Market Cap4330.42M
  • Volume912346
  • P/E Ratio-
  • Dividend Yield-%
  • Revenue TTM0.00000M
  • Revenue Per Share TTM-
  • Gross Profit TTM 0.00000M
  • Diluted EPS TTM-2.42

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Income before tax -81.85400M -46.33800M -14.55600M -11.80900M
Minority interest - - - -
Net income -73.34600M -46.33800M -14.55600M -11.80900M
Selling general administrative 22.38M 10.26M 1.50M 0.61M
Selling and marketing expenses - - - -
Gross profit - - - -
Reconciled depreciation - - - -
Ebit -86.10800M -45.81700M -16.90500M -10.35800M
Ebitda -86.10800M -45.81700M -16.90500M -10.35800M
Depreciation and amortization 8.51M -0.30600M 2.35M -1.45100M
Non operating income net other 4.25M -0.52100M - -
Operating income -86.10800M -45.81700M -16.90500M -10.35800M
Other operating expenses 86.11M 45.82M 16.91M 10.36M
Interest expense 4.25M 0.52M 0.00000M 0.00000M
Tax provision - - - -
Interest income 4.25M - - -
Net interest income 4.25M - - -
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense -8.50800M 0.52M -2.34900M 1.45M
Total revenue 0.00000M 0.00000M 0.00000M 0.00000M
Total operating expenses 86.11M 45.82M 16.91M 10.36M
Cost of revenue - - - -
Total other income expense net 4.25M -0.52100M 2.35M -1.45100M
Discontinued operations - - - -
Net income from continuing ops -81.85400M -46.33800M -14.55600M -11.80900M
Net income applicable to common shares -81.85400M -46.33800M -14.55600M -11.80900M
Preferred stock and other adjustments - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 732.38M 482.46M 293.82M 10.65M 3.32M
Intangible assets - - - - -
Earning assets - - - - -
Other current assets 6.58M 5.83M 2.52M 0.31M 0.30M
Total liab 31.82M 19.48M 8.79M 41.97M 20.57M
Total stockholder equity 700.56M 462.98M 285.04M -31.32300M -17.25600M
Deferred long term liab - - - - -
Other current liab 22.55M 12.29M 5.89M 3.13M 3.63M
Common stock 0.00700M 0.00600M 0.00500M 0.00200M 0.00100M
Capital stock 0.00700M 0.00600M 0.00500M 0.00000M 0.00000M
Retained earnings -286.29600M -160.07700M -78.22300M -31.88500M -17.32900M
Other liab - - - - -
Good will - - - - -
Other assets 0.00000M 4.47M 3.20M - -
Cash 335.39M 241.81M 68.53M 10.33M 3.02M
Cash and equivalents - - - - -
Total current liabilities 31.82M 19.48M 8.79M 4.38M 4.35M
Current deferred revenue - - - - -
Net debt -335.38700M -241.80600M -68.52600M -8.09700M -0.84300M
Short term debt - - - - -
Short long term debt - - - - -
Short long term debt total - - - 2.23M 2.17M
Other stockholder equity 986.82M 623.54M 69.66M 0.56M 0.07M
Property plant equipment - - - - -
Total current assets 726.49M 477.99M 290.63M 10.65M 3.32M
Long term investments - - - - -
Net tangible assets - 462.98M 285.04M -31.32300M -17.25600M
Short term investments 384.52M 230.36M 219.59M - -
Net receivables - 4.47M 3.20M - -
Long term debt - - - 2.23M 2.17M
Inventory - - - - -
Accounts payable 9.27M 7.20M 2.89M 1.25M 0.72M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.03M -0.49400M -0.22800M - -
Additional paid in capital - - - - -
Common stock total equity - 0.00600M 0.00500M - -
Preferred stock total equity - - - - -
Retained earnings total equity - -160.07700M -78.22300M - -
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 5.90M 4.47M 3.20M - -
Deferred long term asset charges - - - - -
Non current assets total 5.90M 4.47M 3.20M 0.00000M 0.00000M
Capital lease obligations - - - - -
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Investments -10.66500M -220.02800M -220.02800M -220.02800M
Change to liabilities 9.69M 5.39M 0.53M 0.42M
Total cashflows from investing activities -10.66500M -220.02800M -220.02800M -220.02800M
Net borrowings - 0.28M -0.25000M -0.25000M
Total cash from financing activities 248.92M 318.22M 22.27M 22.27M
Change to operating activities 2.72M 0.30M 0.74M 0.14M
Net income -81.85400M -46.33800M -14.55600M -11.80900M
Change in cash 173.28M 58.19M 7.32M -9.63900M
Begin period cash flow 68.53M 10.33M 3.02M 12.65M
End period cash flow 241.81M 68.53M 10.33M 3.02M
Total cash from operating activities -64.97100M -40.00000M -14.94900M -9.63900M
Issuance of capital stock 248.63M 321.92M 22.50M 0.00000M
Depreciation -0.37300M 0.21M - -
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock 249.83M 318.91M - -
Other cashflows from financing activities 0.29M 140.95M 22.52M -3.99600M
Change to netincome 10.32M 3.55M -1.66000M 1.61M
Capital expenditures 0.00000M 0.00000M 0.00000M 0.00000M
Change receivables - - - -
Cash flows other operating -2.76300M -2.81600M - -
Exchange rate changes - - - -
Cash and cash equivalents changes 173.28M 58.19M - -
Change in working capital 6.93M 1.94M 1.27M 0.56M
Stock based compensation 10.32M 3.55M 0.73M 0.04M
Other non cash items -0.37300M 0.85M -2.38900M 1.57M
Free cash flow -64.97100M -40.00000M -14.94900M -9.63900M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to EBITDA (x)
NUVL
Nuvalent Inc		 3.84 4.26% 94.02 - - - 5.99 -23.2599
NVO
Novo Nordisk A/S		 1.75 4.17% 43.75 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.78 4.22% 44.00 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 13.40 3.13% 441.74 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 9.78 1.58% 628.73 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

Nuvalent Inc

One Broadway, Cambridge, MA, United States, 02142

Key Executives

Name Title Year Born
Dr. James R. Porter Ph.D. CEO, Pres & Director 1976
Prof. Matthew D. Shair Ph.D. Founder, Head of Scientific Advisory Board & Director 1969
Ms. Deborah Ann Miller J.D., Ph.D. Chief Legal Officer & Sec. 1976
Dr. Christopher D. Turner M.D. Chief Medical Officer 1969
Ms. Alex Balcom CPA, M.B.A. CFO & Treasurer 1985
Dr. Benjamin Lane Sr. VP of Technical Operations NA
Mr. Matthew Metivier VP of HR NA
Ms. Darlene Noci Chief Devel. Officer 1977
Dr. James R. Porter Ph.D. CEO, President & Director 1976
Dr. Benjamin Lane Ph.D. Senior Vice President of Technical Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.